AR045957A1 - Composicion farmaceutica y combinacion - Google Patents
Composicion farmaceutica y combinacionInfo
- Publication number
- AR045957A1 AR045957A1 ARP040103556A ARP040103556A AR045957A1 AR 045957 A1 AR045957 A1 AR 045957A1 AR P040103556 A ARP040103556 A AR P040103556A AR P040103556 A ARP040103556 A AR P040103556A AR 045957 A1 AR045957 A1 AR 045957A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition
- prodrug
- salt
- mycophenolic acid
- combination
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 6
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 abstract 4
- 229960000951 mycophenolic acid Drugs 0.000 abstract 4
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical group OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 abstract 4
- 229940002612 prodrug Drugs 0.000 abstract 4
- 239000000651 prodrug Substances 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 239000002245 particle Substances 0.000 abstract 3
- 230000002265 prevention Effects 0.000 abstract 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000002702 enteric coating Substances 0.000 abstract 1
- 238000009505 enteric coating Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 1
- 229960002930 sirolimus Drugs 0.000 abstract 1
- 230000009261 transgenic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0323202A GB0323202D0 (en) | 2003-10-03 | 2003-10-03 | Organic compounds |
| GB0323598A GB0323598D0 (en) | 2003-10-08 | 2003-10-08 | Organic compounds |
| GB0329852A GB0329852D0 (en) | 2003-12-23 | 2003-12-23 | Organic compounds |
| GB0405902A GB0405902D0 (en) | 2004-03-16 | 2004-03-16 | Organic compounds |
| GB0410714A GB0410714D0 (en) | 2004-05-13 | 2004-05-13 | Organic compounds |
| GB0419356A GB0419356D0 (en) | 2004-08-31 | 2004-08-31 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045957A1 true AR045957A1 (es) | 2005-11-16 |
Family
ID=34437795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103556A AR045957A1 (es) | 2003-10-03 | 2004-09-30 | Composicion farmaceutica y combinacion |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20070036857A1 (enExample) |
| EP (1) | EP1670437A1 (enExample) |
| JP (1) | JP2007507458A (enExample) |
| AR (1) | AR045957A1 (enExample) |
| AU (1) | AU2004280078B2 (enExample) |
| BR (1) | BRPI0414864A (enExample) |
| CA (1) | CA2538099A1 (enExample) |
| MX (1) | MXPA06003646A (enExample) |
| PE (1) | PE20050755A1 (enExample) |
| TW (1) | TW200520759A (enExample) |
| WO (1) | WO2005034916A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1478648E (pt) | 2002-02-01 | 2014-07-15 | Ariad Pharma Inc | Compostos contendo fósforo e suas utilizações |
| GB0419355D0 (en) * | 2004-08-31 | 2004-09-29 | Novartis Ag | Organic compounds |
| US20060235009A1 (en) | 2005-02-08 | 2006-10-19 | Richard Glickman | Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors |
| GB0523659D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| US20090023805A1 (en) * | 2006-02-13 | 2009-01-22 | Anne Claire Marrast | Method of administration |
| JP2010509400A (ja) * | 2006-11-14 | 2010-03-25 | アリアド・ファーマシューティカルズ・インコーポレイテッド | 経口処方組成物 |
| MX2010001711A (es) * | 2007-08-13 | 2010-03-11 | Panacea Biotec Ltd | Composiciones de liberacion extendida que comprenden micofenolato sodico y procedimientos de las mismas. |
| JP2011513391A (ja) * | 2008-03-05 | 2011-04-28 | パナセア バイオテック リミテッド | ミコフェノラートを含有する徐放性医薬組成物およびその方法 |
| CA2766009A1 (en) * | 2009-06-25 | 2010-12-29 | Danisco A/S | Variant lipolytic enzymes with improved expression, functionality and/or activity |
| EA201270544A1 (ru) * | 2009-10-13 | 2012-09-28 | Тева Фармасьютикал Индастриз Лтд. | Композиции с отсроченным высвобождением |
| US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| ES2663744T3 (es) * | 2011-10-06 | 2018-04-16 | Novartis Ag | Composiciones farmacéuticas que comprenden 40-O-(2-hidroxi)etil-rapamicina |
| US20140105976A1 (en) * | 2012-10-11 | 2014-04-17 | Theravida, Inc. | Pharmaceutical formulations of pilocarpine |
| TW201503912A (zh) | 2013-03-19 | 2015-02-01 | Novartis Ag | 包含癌莫事（ｅｖｅｒｏｌｉｍｕｓ）之醫藥組合物 |
| WO2014167442A1 (en) * | 2013-03-26 | 2014-10-16 | Wockhardt Limited | Pharmaceutical compositions comprising mycophenolic acid or salts thereof |
| US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
| EP3089737B1 (en) | 2013-12-31 | 2021-11-03 | Rapamycin Holdings, LLC | Oral rapamycin nanoparticle preparations and use |
| HUP1400075A2 (hu) | 2014-02-14 | 2015-08-28 | Druggability Technologies Ip Holdco Jersey Ltd | Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói |
| MA40982A (fr) | 2014-11-19 | 2017-09-26 | Biogen Ma Inc | Formulation de bille pharmaceutique comprenant du fumarate de diméthyle |
| CA2986359A1 (en) | 2015-05-20 | 2016-11-24 | Novartis Ag | Pharmaceutical combination of everolimus with dactolisib |
| CN110114070A (zh) | 2016-11-23 | 2019-08-09 | 诺华公司 | 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法 |
| US11633378B2 (en) * | 2017-03-13 | 2023-04-25 | Okava Pharmaceuticals, Inc. | Methods and compositions for delivering mycophenolic acid active agents to non-human mammals |
| US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
| US11446055B1 (en) | 2018-10-18 | 2022-09-20 | Lumoptik, Inc. | Light assisted needle placement system and method |
| CA3242243A1 (en) * | 2021-12-23 | 2023-06-29 | Gencaps Sarl | Drug delivery system comprising monomethyl fumarate |
| WO2023224914A1 (en) * | 2022-05-16 | 2023-11-23 | Mayo Foundation For Medical Education And Research | Assessing and treating caveolinopathy diseases |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5516781A (en) * | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
| CA2086642C (en) * | 1992-01-09 | 2004-06-15 | Randall E. Morris | Method of treating hyperproliferative vascular disease |
| US5283257A (en) * | 1992-07-10 | 1994-02-01 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating hyperproliferative vascular disease |
| EP1475091A1 (en) * | 1993-10-01 | 2004-11-10 | Roche Palo Alto LLC | Mycophenolate mofetil - high dose oral suspensions |
| ID18663A (id) * | 1996-04-12 | 1998-04-30 | Novartis Ag | Komposisi farmasi berlapis enterik |
| CN1233169A (zh) * | 1996-10-14 | 1999-10-27 | 弗·哈夫曼-拉罗切有限公司 | 一种粉末状制剂的制备工艺 |
| US6890546B2 (en) * | 1998-09-24 | 2005-05-10 | Abbott Laboratories | Medical devices containing rapamycin analogs |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| DE60044717D1 (de) * | 1999-05-10 | 2010-09-02 | Paolo Brenner | Kombination von immunsuppressiven substanzen zur behandlung oder vorbeugung von transplantat abstossungen |
| US6565882B2 (en) * | 2000-02-24 | 2003-05-20 | Advancis Pharmaceutical Corp | Antibiotic composition with inhibitor |
| US20030054042A1 (en) * | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
| GB0124953D0 (en) * | 2001-10-17 | 2001-12-05 | Novartis Ag | Organic Compounds |
| BR0306858A (pt) * | 2002-01-10 | 2004-11-03 | Novartis Ag | Sistemas de liberação de drogas para a prevenção e tratamento de doenças vasculares compreendendo rapamicina e derivados da mesma |
| DK1539157T3 (da) * | 2002-09-18 | 2013-10-07 | Univ Pennsylvania | Fremgangsmåde til hæmning af choroidal neovaskularisering |
| EP1556091A1 (en) * | 2002-10-04 | 2005-07-27 | Elan Pharma International Limited | Gamma irradiation of solid nanoparticulate active agents |
| GB0301259D0 (en) * | 2003-01-20 | 2003-02-19 | Novartis Ag | Organic compounds |
| GB0307553D0 (en) * | 2003-04-01 | 2003-05-07 | Novartis Ag | Organic compounds |
-
2004
- 2004-09-30 AR ARP040103556A patent/AR045957A1/es unknown
- 2004-10-01 AU AU2004280078A patent/AU2004280078B2/en not_active Ceased
- 2004-10-01 TW TW093129854A patent/TW200520759A/zh unknown
- 2004-10-01 US US10/570,752 patent/US20070036857A1/en not_active Abandoned
- 2004-10-01 PE PE2004000963A patent/PE20050755A1/es not_active Application Discontinuation
- 2004-10-01 BR BRPI0414864-9A patent/BRPI0414864A/pt not_active IP Right Cessation
- 2004-10-01 CA CA002538099A patent/CA2538099A1/en not_active Abandoned
- 2004-10-01 MX MXPA06003646A patent/MXPA06003646A/es not_active Application Discontinuation
- 2004-10-01 WO PCT/EP2004/010998 patent/WO2005034916A1/en not_active Ceased
- 2004-10-01 JP JP2006530072A patent/JP2007507458A/ja active Pending
- 2004-10-01 EP EP04765757A patent/EP1670437A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| TW200520759A (en) | 2005-07-01 |
| EP1670437A1 (en) | 2006-06-21 |
| CA2538099A1 (en) | 2005-04-21 |
| JP2007507458A (ja) | 2007-03-29 |
| PE20050755A1 (es) | 2005-11-28 |
| AU2004280078B2 (en) | 2008-08-07 |
| BRPI0414864A (pt) | 2006-11-28 |
| US20070036857A1 (en) | 2007-02-15 |
| MXPA06003646A (es) | 2006-06-05 |
| AU2004280078A1 (en) | 2005-04-21 |
| WO2005034916A1 (en) | 2005-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR045957A1 (es) | Composicion farmaceutica y combinacion | |
| MX395136B (es) | Composiciones farmaceuticas y metodos de administracion relacionados. | |
| AR080721A1 (es) | 1-((3-ciano-piridin-2-il) metil]-3-metil-7-(2-butin-1-il)-8- (3-(r)- amino-piperidin-1-il)- xantina para tratamiento de un trastorno metabolico de un animal no humano predominantemente carnivoro | |
| WO2012112982A3 (en) | Hydrogel encapsulated cells and anti-inflammatory drugs | |
| PE20180130A1 (es) | Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a | |
| WO2011118976A3 (en) | Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same | |
| PE20120371A1 (es) | 3-[4-(7h-pirrolo[2,3-d]pirimidin-4il)-1h-pirazol-1-il]octano o heptano-nitrilo como inhibidores de jak | |
| ATE499934T1 (de) | Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebs | |
| MX2024000828A (es) | Formulaciones de parasiticida de isoxazolina y metodos para el tratamiento de la blefaritis. | |
| WO2014165607A3 (en) | Aromatic-cationic peptide formulations, compositions and methods of use | |
| ATE554778T1 (de) | Verfahren, pharmazeutische zusammensetzungen und hergestellte artikel zur verabreichung von therapeutischen zellen an das zentrale nervensystem eines tiers | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| WO2010082787A2 (ko) | 연골줄기세포를 유효성분으로 포함하는 골질환 치료용 또는 항염증용 약제학적 조성물 | |
| RU2020121715A (ru) | Синтез эластического волокна in vivo | |
| WO2011116139A3 (en) | Improved pharmaceutical compositions comprising cck- 8 and methods of delivery | |
| MX2010001711A (es) | Composiciones de liberacion extendida que comprenden micofenolato sodico y procedimientos de las mismas. | |
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| CL2008002984A1 (es) | Composicion farmaceutica que comprende micofenolato sodico y su uso para el tratamiento y/o prevencion en enfermedades autoinmunes tales como el rechazo de aloinjertos o xenoinjertos de organos, celulas o tejidos y como antiinflamatorio. | |
| PE20060507A1 (es) | Composicion farmaceutica que contiene acido micofenolico con recubrimiento de liberacion modificada | |
| WO2014165723A3 (en) | Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells | |
| MX418886B (es) | Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo | |
| EP1829882A3 (en) | Epimers and isomers of tetrazole containing rapamycin analogs, methods of making and using the same | |
| MX2021003681A (es) | Composiciones y metodos para el tratamiento de desordenes inflamatorios. | |
| UY30847A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
| ES2702578T3 (es) | Tratamiento de la inflamación dérmica crónica con norketotifeno |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |